New York/Paris, 25 March 2013 – NYSE Euronext announced that international pharmaceutical company Eli Lilly and Company (ticker: LLY), based in Indianapolis, Indiana (USA), completed its listing on NYSE Euronext Paris today. Eli Lilly and Company is the seventeenth company already listed in the United States to join the European platform since the streamlined, cost-effective Fast Path process was adopted. On 27 February 2013, the company announced its decision to delist from the London Stock Exchange on 27 March this year. Eli Lilly and Company maintains its principal listing on the New York Stock Exchange.
NYSE Euronext welcomes NYSE-listed Eli Lilly and Company to its European market
Eli Lilly and Company is an innovation-driven company that discovers, develops, manufactures, and markets products in two business segments – human pharmaceutical products and animal health products. It employs more than 38,000 people worldwide and sells its products in approximately 130 countries.
Eli Lilly and Company was listed on NYSE Euronext Paris through the admission to trading of the 1.1 billion shares making up the company’s capital stock, representing a total market capitalisation of approximately EUR 48.6 billion / USD 62.9 billion.
“We are delighted to welcome Eli Lilly and Company to our European market and in so doing promote biotechnology as a cutting-edge industry and priority ” said Diederik Zandstra, Head of the European Corporate Client Group at NYSE Euronext.
Background on cross-listing on NYSE Euronext European markets
o NYSE Euronext is the first and only exchange group to offer a truly global cross-market listing, trading and visibility platform, providing cost-effective, convenient access to investors and business partners in the US and in Europe.
o NYSE Euronext is the first exchange group to offer companies the ability to trade and raise capital in € and $ and reach investors and constituents directly across continents and multiple time zones, regions and countries.
o Valuable for any company looking to enhance its global profile, support an international business or expand its non-US investor base, a Fast Path listing provides an easy, cost-effective way to gain a European trading presence. Euronext regulators accept documentation, previously filed with the SEC, to comply with the EU Prospectus Directive. With Fast Path, a company avoids the need to draft and translate a separate prospectus in order to be admitted to trading. Documents filed with the SEC serve as the primary component to obtain approval from the competent Euronext regulator. The SEC documentation is combined with a summary “wrapper”, addressing any additional European and local requirements, forming the company’s European prospectus.
Caroline Tourrier: +33 (0)1 49 27 10 82
About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets – the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca – represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: www.nyx.com
None of the information contained in this press release constitutes an offer, solicitation or recommendation to acquire or dispose of any security or investment or to engage in any other transaction or to provide legal, tax, accounting or investment advice or services regarding the suitability or profitability of any security or investment. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by NYSE Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. NYSE Euronext offers no view on whether investments are appropriate for you and recommends you obtain independent advice in respect of such investments. Persons wishing to trade products available on NYSE Euronext markets or wishing to offer such products to third parties (whether by way of admission to listing and/or trading of products, or otherwise) are advised, before doing so, to check their legal and regulatory position in the relevant territory and to understand the related risks. NYSE Euronext does not make any recommendations regarding the merit of any company, security or other financial product or investment identified in this press release. Similarly, NYSE Euronext does not make any recommendation regarding the purchase or sale of any company, security, financial product or investment, endorsed or sponsored by any company identified in this press release. This press release is not intended to be, and shall not constitute in any way a binding or legal agreement, or impose any legal obligation or duty on NYSE Euronext or any of its affiliates. This press release speaks only as of this date. NYSE Euronext disclaims any duty to update the information herein.
NYSE Euronext refers to NYSE Euronext and its affiliates and references to NYSE Euronext in this publication include each and any such company as the context dictates. NYSE Euronext, New York Stock Exchange, NYSE MKT, NYSE Alternext, NYSE Arca and NYSE Liffe are registered marks of NYSE Euronext. © 2013, NYSE Euronext – All rights reserved.